Angioedema caused by oral paliperidone augmentation in the major depressive disorder treatment: a case report

Angioedema is a rare but life-threatening condition characterized by swelling in subcutaneous tissues and mucosa.Paliperidone is an effective treatment option for treatment-resistant patients with depression. While the most commonadverse effect caused by medication is headaches, it is also less likely to observe edema or anaphylactic reaction. In thiscase report, an adolescent diagnosed with major depression and suffered from angioedema following oral paliperidoneaugmentation during the treatment was presented. Edema regressed spontaneously about 24-30 hours following thelast drug intake. No significant laboratory finding that could explain this condition was found. The patient no longersuffered from a similar problem following discontinuation of paliperidone. This case suggests that the clinician shouldbe alerted against possible allergic reactions by reason of oral usage of paliperidone in adolescents and further studies are needed to explore the underlying mechanisms of allergic responses for these patients.

PDF

___

1. Dilbaz N, Darcin AE. A novel technology in treatment with antipsychotic drugs; paliperidone. Bulletin of Clinical Psychopharmacology 2009;19(Suppl. 2):S316-S325. (Turkish)
2. Capasso A, Milano W. Paliperidone in the treatment of Schizophrenia: An overview. Current Neurobiology. 2012;3(2):133- 50.
3. Banerji A, Sheffer AL. The spectrum of chronic angioedema. Allergy Asthma Proc. 2009;30(1):11-6. [CrossRef]
4. Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-65. [CrossRef]
5. Peris TS, Bergman RL, Asarnow JR, Langley A, McCracken JT, Piacentini J. Clinical and cognitive correlates of depressive symptoms among youth with obsessive compulsive disorder. J Clin Child Adolesc Psychol. 2010;39(5):616-26. [CrossRef]
6. Yang FW, Liang CS. Paliperidone augmentation for treatmentresistant depression: a case report. J Clin Psychopharmacol. 2011;31(2):245-6. [CrossRef]
7. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol. 1999;39(3):297-309.
8. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599-613. [CrossRef]
9. Koleva HK, Erickson MA, Vanderlip ER, Tansey J, Mac J, Fiedorowicz JG. 3 case reports of edema associated with quetiapine. Ann Clin Psychiatry. 2009;21(2):77-80.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. [CrossRef]
11. Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2002;109(6):395-402. [CrossRef]
12. Yucel A, Yucel N, Ozcan H, Saritemur M. Dose-dependent paliperidone associated with angioedema. J Clin Psychopharmacol. 2015;35(5):615-6. [CrossRef]
13. Savitz A, Lane R, Nuamah I, Singh J, Hough D, Gopal S. Longterm safety of paliperidone extended release in adolescents with schizophrenia: an open-label, flexible dose study. J Child Adolesc Psychopharmacol. 2015;25(7):548-57. [CrossRef]
14. Joshi G, Petty C, Wozniak J, Faraone SV, Spencer AE, Woodworth KY, Shelley-Abrahamson R, McKillop H, Furtak SL, Biederman J. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology (Berl). 2013;227(3):449-58. [CrossRef]